---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-047493"
form_type: "8-K"
ticker: "SCNI"
cik: "0001611747"
company_name: "Scinai Immunotherapeutics Ltd."
filed_at: "2023-06-08T23:59:59+00:00"
generated_at: "2026-06-14T04:59:15.616391+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BiondVax enters exclusive worldwide license for IL-17 NanoAbs from Max Planck and UMG

## Summary
- Exclusive worldwide license to develop and commercialize VHH antibodies (NanoAbs) targeting IL-17 for all indications.
- Within 45 days of June 4, 2023, BiondVax will issue 17,000 American Depositary Shares to licensors, with a 1-year lock-up.
- Milestone payments due upon IND submission and clinical study initiations; royalties on net sales apply.
- BiondVax must submit an IND by June 30, 2025, or face termination by December 31, 2026, unless extended via EUR 500,000 payments.
- Plans to initiate a preclinical in vivo efficacy study in 2024.

## SEC filing metadata
- accession: 0001213900-23-047493
- form_type: 8-K
- ticker: SCNI
- cik: 0001611747
- company_name: Scinai Immunotherapeutics Ltd.
- filed_at: 2023-06-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1611747/000121390023047493/0001213900-23-047493-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1611747/000121390023047493/ea180017-8k_biondvax.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-047493
- JSON: https://secwatch.observer/filing/0001213900-23-047493.json
- Plain text: https://secwatch.observer/filing/0001213900-23-047493.txt

## Key facts
- Material Agreements
  Scinai Immunotherapeutics Ltd. entered into License Agreement with Max-Planck-Innovation GmbH and the University Medical Center Gottingen (effective 2023-06-04).
  - Action: entry
  - Agreement: license
  - Counterparty: Max-Planck-Innovation GmbH and the University Medical Center Gottingen
  - Effective: 2023-06-04
  source text: On June 4, 2023, BiondVax Pharmaceuticals Ltd. (the “Company” or “BiondVax”) entered into a License Agreement (the “License Agreement”) with the Max-Planck-Innovation GmbH, the technology transfer agency of the Max Planck Society in Germany(“MI”) and the University Medical Center Gottingen (“UMG”) to develop and commercialize VHH antibodies (NanoAbs) targeting Interleukin-17 (IL-17) (the “Target”) as treatments for all potential indications.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1611747/000121390023047493/0001213900-23-047493-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.